Concurrent Chemoradiation with and Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma: A Retrospective Analysis

JY Hsiang,K Liu,S Iganej,J Kaptein,JG Hsiang,JM Hwang,M Tome
DOI: https://doi.org/10.1200/jco.2004.22.90140.5619
IF: 45.3
2004-01-01
Journal of Clinical Oncology
Abstract:5619 Background: Randomized trials have reported improved outcome by adding chemotherapy to radiation, but none have examined concurrent chemoradiation with and without adjuvant chemotherapy. This retrospective analysis seeks to review our experience. Methods: Records of 29 consecutively treated patients from 1997 to 2002 were reviewed; these included stage IIII(n=8) and stage IV(n=21) patients with a median age of 49years. All patients received concurrent chemoradiation with the majority (82.8%) receiving at least three courses of cisplatin(100mg/m2;days1,22,43). Seventeen patients received adjuvant chemotherapy with cisplatin(80mg/m2;day1) and fluorouracil(1000mg/m2/d;days1–4) every 4 weeks, with a majority(82.4%) receiving at least three courses. Twelve patients did not receive adjuvant chemotherapy. All patients received radiotherapy in 1.8–2.0 Gy/d fractions to 7020Gy median total dose. Results: After a median follow-up of 39.6 months, seven of 29 patients had recurrent(n=6)/persistent disease(n=1). At last follow-up, six patients had died (four of disease, one treatment related, one of intercurrent death). Four patients developed distant metastases: three had no other sites of relapse and one had recurred locally first. Three of the four patients with distant metastases had adjuvant chemotherapy. The median time to relapse was 15.4 months. The 3-year disease-free survival (DFS) and overall survival (OS) for the 29 patients were 77% and 83% respectively. The 3-year DFS for those with and without adjuvant chemotherapy was 78% and 82%(p=0.5), while OS was 85% and 92%(p=0.8), respectively. Patients with adjuvant chemotherapy more frequently had significant weight loss and xerostomia. Conclusions: Our data suggests that concurrent chemoradiation with or without adjuvant chemotherapy provide similar outcomes. However patients with adjuvant chemotherapy are more likely to develop significant weight loss and xerostomia, and they may be at increased risk of treatment-related deaths. Randomized trials are needed to confirm these findings. No significant financial relationships to disclose.
What problem does this paper attempt to address?